Bayer stock faces split Q3 test as estimates diverge

Published on 11/02/2026 at 09:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Bayer stock enters a key reporting week before third-quarter results on Tuesday. JPMorgan sees stronger sales but weaker division-level profitability.

Bayer faces a split earnings test

Bayer will publish its third-quarter 2026 results before the market update on November 3.
JPMorgan expects revenue above consensus but lower EBITDA in pharmaceuticals and agriculture.
Management commentary and the full-year outlook will shape the market's next assessment.

Bayer, DE000BAY0017, Illustration mit AI erstellt.

Bayer will publish its third-quarter 2026 results on Tuesday, November 3, with revenue, operating profit and the full-year outlook in focus. The company's official Bayer Q3 2026 Media Update says the news release and quarterly statement will be available from 7:30 a.m. CET.

The Ad Hoc News report says JPMorgan expects Bayer's revenue to come in 2 percent above consensus. At the same time, the bank forecasts EBITDA in the pharmaceuticals and agriculture divisions 6 percent below consensus.

Revenue and profit may diverge

The split forecast leaves investors with two separate tests. Stronger-than-expected sales would not automatically produce a positive operating-profit surprise if costs, product mix or divisional conditions weigh on EBITDA. The analyst view is a forecast, not a result, and the quarterly statement will determine whether the gap appears in Bayer's reported figures.

JPMorgan reaffirmed its Overweight rating and a 61 euro price target, according to the report. The bank also expects management to maintain its full-year guidance. That expectation is not a raised outlook, so the wording of the guidance and the explanation behind it will matter alongside the headline numbers.

Management commentary follows results

Bayer plans a live media update at 10:00 a.m. CET on November 3, with remarks from CEO Bill Anderson and CFO Judith Hartmann followed by questions and answers. The company says a recording should be available at approximately 2:00 p.m. CET.

The earlier analysis also separates longer-term pipeline progress from near-term earnings. Regulatory developments and research milestones may support the broader investment case, but the November report will provide the next direct read on operating performance.

The real-time quote of Bayer stock traded at 49.65 euros on Lang & Schwarz at 09:10 CET on Monday, November 2, 2026, 1.84 percent below the Xetra close of Friday, October 30.